https://doi.org/10.55788/ba2d7a79
Dapagliflozin has been demonstrated to decrease clinical events in patients with stable HFrEF and recent data suggests that early clinical benefits may also be expected with this therapy [1]. To assess whether dapagliflozin indeed offers such early benefits for patients, Prof. Julio NĂșñez Villota (University of Valencia, Spain) and co-investigators designed the multicentre, randomised DAPA-VO2 trial (NCT04197635) [2]. In this study, 90 patients with stable HFrEF were randomised 1:1 to placebo or dapagliflozin in addition to guideline-directed medical therapy. The primary endpoint was the change in peakVO2 after 1 and 3 months. Prof. NĂșñez Villota emphasised that 2 out of 3 patients were on triple pharmacological therapy.
Dapagliflozin treatment significantly improved peakVO2 in HFrEF patients compared with placebo treatment after 1 month (Îmean change 1.09 mL/kg/min; P=0.021) and after 3 months (1.06; P=0.032). However, secondary endpoint measurements did not demonstrate clinical benefits of dapagliflozin over placebo after 1 month: 6-minute walk test (6MWT) (375.1 m vs 357.4 m; P=0.471), Minnesota Living with Heart Failure Questionnaire (MLHFQ) (24.0 vs 18.9; P=0.220), left ventricular ejection fraction (LVEF) (35.1 vs 35.6; P=0.882). Similarly, after 3 months, dapagliflozin treatment did not result in clinical benefits as per secondary outcome measures over the patients in the placebo arm; however, the study was not powered to detect differences at the magnitude seen in the pivotal phase 3 trial.
This is a small study, so firm conclusions cannot be drawn. âNonetheless, among patients with stable HFrEF dapagliflozin resulted in a significant improvement in the primary endpoint of this study, change in peakVO2, at 1 and 3 months,â concluded Prof. NĂșñez Villota.
- Berg DD, et al. JAMA Cardiol. 2021;6(5):499â507.
- Palau P, et al. Short-term Effects of Dapagliflozin on Peak VO2 in Heart failure and Reduced Ejection Fraction (DAPA-VO2): a Randomized Clinical Trial. LBT Pharmacological treatment II, Heart Failure 2022, 21â24 May, Madrid, Spain.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Significant improvement in BP from istaroxime, a novel non-adrenergic agent Next Article
FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status »
« Significant improvement in BP from istaroxime, a novel non-adrenergic agent Next Article
FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status »
Table of Contents: HFA 2022
Featured articles
Phase 3 and 4 Trials
GALACTIC-HF: Omecamtiv mecarbil as option for HFrEF patients with low SBP
HELIOS-A: Vutrisiran meets exploratory endpoints
Patiromer helps HFrEF patients to optimise RAAS inhibitors without hyperkalaemia
FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status
DAPA-VO2: Rapid effect of dapagliflozin on peak VO2 in stable HFrEF
Phase 1/2 Trials
Significant improvement in BP from istaroxime, a novel non-adrenergic agent
SERENADE: Macitentan fails in HFpEF plus PAH
Combination of filgrastim and dutogliptin appears safe in STEMI
Therapeutic Devices
Cardiac contractility modulation therapy promising for patients with HFpEF
REBALANCE-HF: Encouraging observations for splanchnic nerve ablation in HFpEF
Updates on SGLT2 Inhibitors
DAPA-HF: Dapagliflozin is safe and efficacious in frail patients
EMPEROR-Preserved: Empagliflozin stable across age groups
EMPULSE: Empagliflozin delivers rapid and clinically meaningful decongestion
Dapagliflozin performs consistently across LVEF in HF
Miscellaneous Topics
Cardiac wasting relevant for clinical outcomes in cancer
Urocortin-2 a potential treatment target for HFpEF
Should ATTR-CM be added to the differential diagnosis of patients with HF?
Delayed initiation of novel GDMTs associated with adverse outcomes in HF patients
Related Articles
August 19, 2021
Vericiguat effective irrespective of atrial fibrillation status
October 30, 2023
Heart failure: the 2023 update
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy